Mycoplasma genitalium gyrA mutation confers resistance to fluoroquinolones

Accession ARO:3004631
DefinitionMycoplasma Genitalium GyrA mutations confers resistance to fluoroquinolones such as Moxifloxacin.
AMR Gene Familyfluoroquinolone resistant gyrA
Drug Classfluoroquinolone antibiotic
Resistance Mechanismantibiotic target alteration
Classification12 ontology terms | Show
Parent Term(s)2 ontology terms | Show
+ confers_resistance_to_drug_class fluoroquinolone antibiotic [Drug Class]
+ fluoroquinolone resistant gyrA [AMR Gene Family]
Publications

Tagg KA, et al. 2013. J. Clin. Microbiol. 51(7):2245-9 Fluoroquinolone and macrolide resistance-associated mutations in Mycoplasma genitalium. (PMID 23658265)

Bébéar CM, et al. 2003. Antimicrob. Agents Chemother. 47(10):3323-5 DNA gyrase and topoisomerase IV mutations in clinical isolates of Ureaplasma spp. and Mycoplasma hominis resistant to fluoroquinolones. (PMID 14506049)

Gruson D, et al. 2005. Antimicrob Agents Chemother 49(3): 1190-1193. In vitro development of resistance to six and four fluoroquinolones in Mycoplasma pneumoniae and Mycoplasma hominis, respectively. (PMID 15728924)

Hamasuna R, et al. 2018. PLoS ONE 13(6):e0198355 Mutations in ParC and GyrA of moxifloxacin-resistant and susceptible Mycoplasma genitalium strains. (PMID 29883482)

Resistomes

Prevalence of Mycoplasma genitalium gyrA mutation confers resistance to fluoroquinolones among the sequenced genomes, plasmids, and whole-genome shotgun assemblies available at NCBI for 82 important pathogens (see methodological details and complete list of analyzed pathogens). Values reflect percentage of genomes, plasmids, or whole-genome shotgun assemblies that have at least one hit to the AMR detection model. Default view includes percentages calculated based on Perfect plus Strict RGI hits. Select the checkbox to view percentages based on only Perfect matches to AMR reference sequences curated in CARD (note: this excludes resistance via mutation as references in protein variant models are often wild-type, sensitive sequences).

Prevalence: protein variant model

SpeciesNCBI ChromosomeNCBI PlasmidNCBI WGS
No prevalence data


Detection Models

Model Type: protein variant model

Model Definition: The protein variant model is an AMR detection model. Protein variant models are similar to protein homolog models - they detect the presence of a protein sequence based on its similarity to a curated reference sequence, but secondarily search submitted query sequences for curated sets of mutations shown clinically to confer resistance relative to wild-type. This model includes a protein reference sequence, a curated BLASTP cut-off, and mapped resistance variants. Mapped resistance variants may include any or all of: single resistance variants, insertions, deletions, co-dependent resistance variants, nonsense SNPs, and/or frameshift mutations. Protein variant model matches to reference sequences are categorized on two criteria: strict and loose. A strict match has a BLASTP bitscore above the curated BLASTP cutoff value and contains at least one detected mutation from amongst the mapped resistance variants; a loose match has a BLASTP bitscore below the curated BLASTP cutoff value but still contains at least one detected mutation from amongst the mapped resistance variants. Regardless of BLASTP bitscore, if a sequence does not contain one of the mapped resistance variants, it is not considered a match and not detected by the protein variant model.

Legend:

  • discovered in clinical, agricultural, or environmental isolates
  • discovered via laboratory selection experiments


Bit-score Cut-off (blastP): 1400


>gb|AAC71220.1|+|Mycoplasma Genitalium GyrA mutation confers resistance to fluoroquinolones [Mycoplasma genitalium G37]
MAKQQDQVDKIRENLDNSTVKSISLANELERSFMEYAMSVIVARALPDARDGLKPVHRRV
LYGAYIGGMHHDRPFKKSARIVGDVMSKFHPHGDMAIYDTMSRMAQDFSLRYLLIDGHGN
FGSIDGDRPAAQRYTEARLSKLAAELLKDIDKDTVDFIANYDGEEKEPTVLPAAFPNLLA
NGSSGIAVGMSTSIPSHNLSELIAGLIMLIDNPQCTFQELLTVIKGPDFPTGANIIYTKG
IESYFETGKGNVVIRSKVEIEQLQTRSALVVTEIPYMVNKTTLIEKIVELVKAEEISGIA
DIRDESSREGIRLVIEVKRDTVPEVLLNQLFKSTRLQVRFPVNMLALVKGAPVLLNMKQA
LEVYLDHQIDVLVRKTKFVLNKQQERYHILSGLLIAALNIDEVVAIIKKSANNQEAINTL
NTKFKLDEIQAKAVLDMRLRSLSVLEVNKLQTEQKELKDSIEFCKKVLADQKLQLKIIKE
ELQKINDQFGDERRSEILYDISEEIDDESLIKVENVVITMSTNGYLKRIGVDAYNLQHRG
GVGVKGLTTYVDDSISQLLVCSTHSDLLFFTDKGKVYRIRAHQIPYGFRTNKGIPAVNLI
KIEKDERICSLLSVNNYDDGYFFFCTKNGIVKRTSLNEFINILSNGKRAISFDDNDTLYS
VIKTHGNDEIFIGSTNGFVVRFHENQLRVLSRTARGVFGISLNKGEFVNGLSTSSNGSLL
LSVGQNGIGKLTSIDKYRLTKRNAKGVKTLRVTDRTGPVVTTTTVFGNEDLLMISSAGKI
VRTSLQELSEQGKNTSGVKLIRLKDNERLERVTIFKEELEDKEMQLEDVGSKQITQ



>gb|L43967.2|+|4812-7322|Mycoplasma Genitalium GyrA mutation confers resistance to fluoroquinolones [Mycoplasma genitalium G37]
ATGGCAAAGCAACAAGATCAAGTAGATAAGATTCGTGAAAACTTAGACAATTCAACTGTCAAAAGTATTTCATTAGCAAATGAACTTGAG
CGTTCATTCATGGAATATGCTATGTCAGTTATTGTTGCTCGTGCTTTACCTGATGCTAGAGATGGACTTAAACCAGTTCATCGTCGTGTT
CTTTATGGTGCTTATATTGGTGGCATGCACCATGATCGTCCTTTTAAAAAGTCTGCGAGGATTGTTGGTGATGTAATGAGTAAATTCCAC
CCTCATGGTGATATGGCAATATATGACACCATGTCAAGAATGGCTCAAGACTTTTCATTAAGATACCTTTTAATTGATGGTCATGGTAAT
TTTGGTTCTATAGATGGTGATAGACCTGCTGCACAACGTTATACAGAAGCAAGATTATCTAAACTTGCAGCAGAACTTTTAAAAGATATT
GATAAAGATACAGTTGACTTTATTGCTAATTATGATGGTGAGGAAAAAGAACCAACTGTTCTACCAGCAGCTTTCCCTAACTTACTTGCA
AATGGTTCTAGTGGGATTGCAGTTGGAATGTCAACATCTATTCCTTCCCATAATCTCTCTGAATTAATTGCGGGTTTAATCATGTTAATT
GATAATCCTCAATGCACTTTTCAAGAATTATTAACTGTAATTAAAGGACCTGATTTTCCAACAGGAGCTAACATTATCTACACAAAAGGA
ATTGAAAGCTACTTTGAAACAGGTAAAGGCAATGTAGTAATTCGTTCTAAAGTTGAGATAGAACAATTGCAAACAAGAAGTGCATTAGTT
GTAACTGAAATTCCTTACATGGTTAACAAAACTACCTTAATTGAAAAGATTGTAGAACTTGTTAAAGCTGAAGAGATTTCAGGAATTGCT
GATATCCGTGATGAATCCTCTCGAGAAGGAATAAGGTTAGTGATTGAAGTAAAACGCGACACTGTACCTGAAGTTTTATTAAATCAACTT
TTTAAATCAACAAGATTACAAGTACGCTTCCCTGTTAATATGCTTGCTTTAGTTAAAGGAGCTCCTGTACTTCTCAACATGAAACAAGCT
TTGGAAGTATATCTTGATCATCAAATTGATGTTCTTGTTAGAAAAACAAAGTTTGTGCTTAATAAACAACAAGAACGTTATCACATTTTA
AGCGGACTTTTAATTGCTGCTTTAAATATTGATGAGGTTGTTGCAATTATTAAAAAATCAGCAAATAACCAGGAAGCAATTAATACATTA
AATACAAAGTTTAAGCTTGATGAAATTCAAGCTAAAGCAGTTCTTGACATGCGTTTAAGGAGCTTAAGCGTACTTGAAGTTAACAAACTT
CAAACTGAACAAAAAGAGTTAAAAGATTCAATTGAATTTTGTAAGAAAGTGTTAGCTGATCAAAAATTACAGCTAAAAATAATCAAAGAG
GAATTGCAAAAAATCAATGATCAGTTTGGTGATGAAAGAAGAAGTGAAATTCTCTATGATATCTCTGAGGAAATTGATGATGAATCATTG
ATAAAAGTTGAGAATGTAGTGATAACTATGTCTACAAATGGTTATCTAAAAAGGATTGGAGTTGATGCTTATAATCTTCAACATCGTGGT
GGAGTTGGGGTTAAAGGGCTAACTACTTATGTTGATGATAGTATTAGTCAATTATTGGTCTGTTCAACTCACTCTGACTTATTATTTTTT
ACTGATAAGGGTAAGGTTTATAGAATTAGAGCTCATCAAATTCCCTATGGTTTTAGAACAAATAAAGGTATTCCCGCTGTTAACTTAATC
AAAATTGAAAAGGATGAAAGAATTTGTTCATTGTTATCTGTTAATAACTATGATGATGGTTATTTCTTTTTCTGTACTAAAAATGGAATT
GTTAAAAGAACGAGCTTGAATGAATTCATCAACATCTTAAGTAATGGTAAGCGGGCTATATCTTTTGATGATAATGACACTTTGTATTCA
GTAATTAAAACCCACGGAAATGATGAGATTTTTATTGGTTCTACCAATGGATTTGTTGTTCGCTTCCATGAAAATCAACTCAGAGTTCTT
TCAAGAACAGCAAGAGGTGTATTTGGTATCAGTTTAAATAAAGGAGAATTTGTTAATGGACTATCAACTTCAAGCAACGGTAGCTTACTT
TTATCAGTCGGTCAAAATGGAATAGGTAAATTAACGAGCATAGATAAATATAGACTCACAAAACGTAATGCTAAGGGAGTTAAAACTCTA
AGGGTTACTGATAGAACAGGCCCTGTTGTTACAACAACCACTGTTTTTGGTAATGAGGATCTTTTAATGATTTCCTCTGCTGGTAAAATT
GTGCGTACCAGTTTACAAGAACTTTCAGAACAAGGTAAAAACACTTCTGGTGTTAAGTTAATTAGATTAAAAGATAATGAACGTTTAGAA
AGAGTAACTATCTTTAAAGAAGAGTTAGAAGACAAAGAAATGCAACTAGAAGATGTTGGATCCAAACAAATTACGCAATAA